Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05166577
Title Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Viracta Therapeutics, Inc.
Indications

nasopharynx carcinoma

Therapies

CHR-3996 + Pembrolizumab + Valganciclovir

CHR-3996 + Valganciclovir

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.